Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$247.61 USD
+4.29 (1.76%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $247.94 +0.33 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/1/24 |
---|---|
Current Quarter | -0.75 |
EPS Last Quarter | -0.16 |
Last EPS Surprise | 78.67% |
ABR | 1.81 |
Earnings ESP
|
9.46% |
---|---|
Current Year | -2.09 |
Next Year | -0.87 |
EPS (TTM) | -2.32 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 452.54M | 460.81M | 1.88B | 2.24B |
# of Estimates | 11 | 11 | 12 | 12 |
High Estimate | 491.13M | 495.50M | 1.94B | 2.53B |
Low Estimate | 430.49M | 443.00M | 1.83B | 1.94B |
Year ago Sales | 318.75M | 750.53M | 1.83B | 1.88B |
Year over Year Growth Est. | 41.97% | -38.60% | 2.59% | 19.39% |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.75 | -0.74 | -2.09 | -0.87 |
# of Estimates | 9 | 9 | 8 | 9 |
Most Recent Consensus | -0.88 | -0.74 | -2.46 | -2.21 |
High Estimate | -0.38 | -0.41 | -1.69 | 1.72 |
Low Estimate | -1.26 | -1.29 | -2.46 | -2.34 |
Year ago EPS | -2.21 | 1.15 | -3.52 | -2.09 |
Year over Year Growth Est. | 66.06% | -164.35% | 40.63% | 58.37% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 1 | 0 | 2 | 0 |
Up Last 60 Days | 1 | 0 | 5 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 1 |
Down Last 30 Days | 1 | 2 | 0 | 2 |
Down Last 60 Days | 3 | 4 | 0 | 4 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.75 | -0.74 | -2.09 | -0.87 |
7 Days Ago | -0.75 | -0.74 | -2.09 | -0.83 |
30 Days Ago | -0.74 | -0.73 | -2.18 | -0.62 |
60 Days Ago | -0.72 | -0.71 | -2.37 | -0.49 |
90 Days Ago | -0.73 | -0.78 | -2.79 | -0.96 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -1.03 | -0.98 | -4.16 | -2.54 |
Zacks Consensus Estimate | -1.21 | -1.15 | -3.92 | -2.52 |
Earnings ESP | 14.88% | 14.78% | -6.12% | -0.79% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.16 | -1.10 | 1.15 | -2.21 | NA |
Estimate | -0.75 | -1.20 | -1.61 | -1.72 | NA |
Difference | 0.59 | 0.10 | 2.76 | -0.49 | 0.74 |
Surprise | 78.67% | 8.33% | 171.43% | -28.49% | 57.49% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more